re: ACE inhibitors and other factors in patients with coronary problems:
American College of Cardiology
....excerpt:
“Stressing the current uncertainty about the virus, the bulletin provides the following clinical guidance:
COVID-19 is spread through droplets and can live for substantial periods outside the body; containment and prevention using standard public health and personal strategies for preventing the spread of communicable disease remains the priority.
In geographies with active COVID-19 transmission (mainly China), it is reasonable to advise patients with underlying cardiovascular disease of the potential increased risk and to encourage additional, reasonable precautions.
Older adults are less likely to present with fever, thus close assessment for other symptoms such as cough or shortness of breath is warranted.
Some experts have suggested that the rigorous use of guideline-directed, plaque-stabilizing agents could offer additional protection to cardiovascular disease (CVD) patients during a widespread outbreak (statins, beta-blockers, ACE inhibitors, acetylsalicylic acid); however, such therapies should be tailored to individual patients....read more at link
All those look good to me except the aspirin one.